🇺🇸 FDA
Pipeline program

TRU-016 (anti-CD37 protein therapeutic)

16007

Phase 1 small_molecule completed

Quick answer

TRU-016 (anti-CD37 protein therapeutic) for Chronic Lymphocytic Leukemia (CLL) is a Phase 1 program (small_molecule) at Aptevo Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aptevo Therapeutics
Indication
Chronic Lymphocytic Leukemia (CLL)
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials